MDX-210 humanized Bispecific antibody targeting the HER-2 receptor: Began a Phase I/II trial in 42 patients at the NCI, to assess safety and toxicity, to determ

Medarex Inc. (MEDX), Annandale, N.J. Product: MDX-210 humanized Bispecific antibody targeting the HER-2 receptor Indication: Cancers over-expressing HER-2 (prostate, breast, pancreatic, ovarian and n...